Nykode Therapeutics (NYKD) Development of APC-targeted antigen-apecific immune tolerance therapies for autoimmune diseases presentation summary

Strategic focus and platform overview

• Precision immunotherapies target antigens to APCs, enabling tailored immune responses for oncology and autoimmune diseases.

• Lead oncology asset in Phase 2 trial for head & neck cancer, with additional late-stage basket trials showing positive data.

• Autoimmune program leverages core technology with strong preclinical data and best-in-class potential.

• Disciplined cost management and robust financial position support advancement to key milestones.

• Publicly listed on Oslo Stock Exchange under ticker NYKD.OL.

Platform design and mechanism of action

• Modular platform includes targeting, antigen, dimerization, and modulatory units for antigen-specific tolerance.

• Delivers therapy as recombinant protein or pDNA, inducing tolerance by targeting disease-causing epitopes to APCs.

• Enables antigen-specific regulation of major immune cells and adapts to diverse autoimmune diseases.

• AI-driven construct design allows inclusion of multiple antigens and bystander suppression.

• Several patent applications filed for these concepts.

Preclinical efficacy and disease models

• Demonstrated strong preclinical efficacy in autoimmune models, including EAE and NOD T1D.

• APC-targeted therapy outperforms non-targeted approaches in disease protection and symptom reduction.

• Reduces effector T cell responses, increases regulatory T cells, and lowers CNS-infiltrating immune cells.

• Shows durable disease amelioration and reduction of auto-antibodies in symptomatic mice.

• Efficacy confirmed in relapsing-remitting EAE and vitiligo models.